<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00897247</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000518348</org_study_id>
    <secondary_id>P30CA022453</secondary_id>
    <secondary_id>WSU-2006-057</secondary_id>
    <secondary_id>WSU-HIC-094806MP2F</secondary_id>
    <nct_id>NCT00897247</nct_id>
  </id_info>
  <brief_title>Biomarkers to Detect Mesothelioma Early in Patients Exposed to Asbestos or Vermiculite</brief_title>
  <official_title>Early Detection Biomarkers for Mesothelioma Among Asbestos and Vermiculite Exposed Populations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of body fluid and blood from patients who have been exposed to
      asbestos or vermiculite in the laboratory may help doctors learn more about changes that may
      occur in DNA and identify biomarkers related to cancer.

      PURPOSE: This laboratory study is looking for biomarkers to detect mesothelioma early in
      patients exposed to asbestos or vermiculite.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Identify patients with known asbestos exposure at early stages of disease development
           (i.e., indolent premalignant pleural plaques and fibrosis vs malignant pleural
           mesothelioma).

        -  Determine the expression levels of tumor-associated proteins in these patients.

        -  Analyze samples of serum and pleural effusions obtained from these patients.

        -  Determine the proteomic profile of samples obtained from these patients.

        -  Determine the molecular mechanisms associated with the regulation of the extracellular
           matrix microenvironment proteins (e.g., osteonectin, intelectin, or matrix
           metalloproteins) involved in disease onset and progression.

      OUTLINE: This is a multicenter study.

      Patients undergo collection of body cavity fluid, including pleural effusion, and blood.
      Specimens, including fresh frozen malignant pleural mesothelioma tumor tissue, if available,
      are analyzed for proteomic profile, gene expression profile, and tumor-associated protein
      expression levels.

      PROJECTED ACCRUAL: A total of 200 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of potential drug targets for therapeutic strategies to treat asbestos fiber-related diseases</measure>
    <time_frame>At time of analysis</time_frame>
  </primary_outcome>
  <enrollment type="Actual">494</enrollment>
  <condition>Malignant Mesothelioma</condition>
  <condition>Pulmonary Complications</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>microarray analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>proteomic profiling</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Exposure to vermiculite or asbestos insulation

               -  Symptomatic or nonsymptomatic exposure-related disease

          -  Seen at a clinic in Libby, Montana (CARD Clinic) or Michigan (COEM)

        PATIENT CHARACTERISTICS:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anil Wali, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>March 4, 2014</last_update_submitted>
  <last_update_submitted_qc>March 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>malignant mesothelioma</keyword>
  <keyword>pulmonary complications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

